TORONTO, ON / ACCESSWIRE / December 6, 2018 / NEXGENRX INC. („NexgenRx“ or the „Company“) announces the grant to certain directors, officers and employees of NexgenRx of an aggregate of 2,700,000 options to acquire common shares in the capital of NexgenRx at a price of $0.25 for a period of 10 years. 1,700,000 of the foregoing options shall vest as to 33.3% each year for three years, beginning on the first anniversary of the grant date. The remaining 1,000,000 of the foregoing options shall vest immediately upon the Corporation’s transaction and administration recurring monthly revenue exceeding $650,000. All of the options granted today (and the common shares issuable upon exercise) will be subject to applicable securities law hold periods.
NexgenRx is Canada’s only independent full service technology solutions provider, offering proprietary full front end enrolment, hour bank and mobile access capabilities, combined with state of the art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide complete proprietary solutions to plan sponsors that need sophisticated front end administration and health benefit technology applications, all in a cost- effective manner. NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at www.nexgenrx.com.
Caution Regarding Forward-Looking Statements – This news release contains certain forward looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Ronald C. Loucks
Kelly Ehler CPA, CA
President and CEO
Chief Financial Officer
SOURCE: NexgenRx Inc.